Bank of Montreal’s Astria Therapeutics ATXS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-111,170
Closed -$1.46M 3752
2025
Q4
$1.46M Buy
+111,170
New +$1.33M ﹤0.01% 1786
2021
Q2
Sell
-108
Closed -$2K 3731
2021
Q1
$2K Sell
108
-426
-80% -$7.7K ﹤0.01% 4889
2020
Q4
$8K Sell
534
-14,186
-96% -$253K ﹤0.01% 4697
2020
Q3
$575K Sell
14,720
-1,224
-8% -$48.5K ﹤0.01% 2273
2020
Q2
$620K Buy
15,944
+885
+6% +$31.5K ﹤0.01% 2151
2020
Q1
$346K Buy
15,059
+1,013
+7% +$31.4K ﹤0.01% 2134
2019
Q4
$498K Buy
+14,046
New +$443K ﹤0.01% 2676
2019
Q2
Sell
-1,590
Closed -$75K 4846
2019
Q1
$75K Buy
+1,590
New +$53.9K ﹤0.01% 3187
2016
Q4
Sell
-83
Closed -$31K 4042
2016
Q3
$31K Buy
+83
New +$21.9K ﹤0.01% 3192

Bank of Montreal's ATXS Position: Q1 2026 in Review

Bank of Montreal sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 111,170 shares — an estimated $1.46M sold.

Bank of Montreal first reported a position in ATXS in Q3 2016 and held it in 9 quarters. The position peaked at $1.46M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

  • Bank of Montreal reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of Montreal sold 111,170 Astria Therapeutics shares in Q1 2026, an estimated $1.46M.
  • Bank of Montreal first reported a position in Astria Therapeutics in Q3 2016 and held it in 9 quarters.
  • Bank of Montreal's Astria Therapeutics position peaked at $1.46M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.